Luis A. Juncos

High Impact

Adjunct Professor of Medicine

UAMS

Also affiliated: Mayo Clinic (1999–2026); Consejo Nacional de Investigaciones Científicas y Técnicas (2010); Minnesota State University, Mankato (2000); Henry Ford Health System (1993–1996); Shandong University (2016); State Street (United States) (2014–2015); Universidad Nacional de Córdoba (1999–2015); Chinese Academy of Medical Sciences & Peking Union Medical College (2017); University of South Florida (2017); Columbia University Irving Medical Center (2019); AdventHealth Orlando (2021–2023); Society of Critical Care Medicine (2025); Jackson Memorial Hospital (2009–2019); Henry Ford Hospital (1991–1998); University of Mississippi Medical Center (2009–2019); University of Alabama at Birmingham (2013); University of Mississippi (2011–2016); Central Arkansas Veterans Healthcare System (2018–2025); Hospital Privado de Comunidad (1994); Centro Científico Tecnológico - San Luis (2012–2016); Anna Needs Neuroblastoma Answers (2013); United States Army Institute of Surgical Research (2008); Mayo Clinic in Arizona (1999–2026); Fresenius Medical Care (United States) (2025–2026); Centro Científico Tecnológico - Córdoba (2012); Hypertension Institute (2010); Hospital de Especialidades (1994); Fresenius Medical Care (India) (2025); G.V. (Sonny) Montgomery VA Medical Center (2012); Office of International Affairs (2025); Institute of Molecular Biology and Biophysics (2011–2015); Hospital Privado (1990–1997); John L. McClellan Memorial Veterans Hospital (2019–2021); Shandong First Medical University (2009); Fresenius Medical Care North America (United States) (2025); Robert Wood Johnson Foundation (2019); Cordoba University (1999–2012); Zhejiang University (2016); Universidad de Murcia (2000–2005); Fresenius Medical Care (Germany) (2025); Florida College (2008–2017)

Faculty Researcher

42 h-index 194 pubs 5,778 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website Research Group

OverviewAI-generated summary

Luis A. Juncos researches acute kidney injury (AKI) and its related conditions, including its diagnosis, prognosis, and treatment. His work has investigated urinary neutrophil gelatinase-associated lipocalin (NGAL) as a marker for AKI in patients with cirrhosis and explored the role of terlipressin in treating hepatorenal syndrome. Juncos has also studied methods to reduce ischemic kidney injury by modulating Na+/K+-ATPase functions and has contributed to understanding the epidemiology and outcomes of AKI treated with continuous kidney replacement therapy through multicenter studies.

His research extends to the pathophysiology of AKI in critical illness and specific conditions like gestational hypertension, where macula densa NOS1β's role in modulating renal hemodynamics and blood pressure during pregnancy is examined. Juncos has also addressed drug-induced osmotic nephropathy, including the potential role of SGLT2-inhibitors. With 193 publications and an h-index of 42, his scholarship has been recognized with a highly cited designation. He collaborates with researchers at the University of Arkansas for Medical Sciences, including Nithin Karakala, Joseph H. Holthoff, Michael Connor, and Christian Herzog.

Metrics

h-index: 42
Publications: 194
Citations: 5,778

Selected Publications

Aldosterone in Diabetic Kidney Disease: From Mineralocorticoid Receptor Antagonism to Aldosterone Synthase Inhibition (2026)

International Journal of Molecular Sciences DOI OpenAlex
185: IS LIPOPROTEIN (A) AN INDEPENDENT PREDICTOR FOR CARDIOGENIC SHOCK? (2026)

Critical Care Medicine DOI OpenAlex
Guilty or Not Guilty (2026)

Kidney360 DOI OpenAlex
The Aging Kidney and Acute Kidney Injury (2025)

Journal of the American Society of Nephrology DOI OpenAlex
Evaluating Real-World Data of CRRT Dose Prescription: Results from the CRRTnet Registry (2025)

Journal of the American Society of Nephrology 1 citation DOI OpenAlex
NAD+-Boosting Ameliorates Heme Protein–Mediated Acute Kidney Injury (2025)

Kidney360 DOI OpenAlex
Plasma Cell–Directed Rescue With Bortezomib in Refractory Antiphospholipase A2 Receptor–Positive Membranous Nephropathy (2025)

Kidney International Reports 4 citations DOI OpenAlex
From Receptor to Repair (2025)

Kidney360 1 citation DOI OpenAlex
The role of IGFBP-1 in the clinical prognosis and pathophysiology of acute kidney injury (2025)

American Journal of Physiology-Renal Physiology 3 citations DOI OpenAlex
ACE2 deficiency protects against heme protein-induced acute kidney injury (2025)

American Journal of Physiology-Renal Physiology 3 citations DOI OpenAlex
The Occurrence of Senescence in the Arteriovenous Fistula in the Rat (2024)

Kidney360 6 citations DOI OpenAlex
Semaglutide (Ozempic), a Possible Cause of Focal Segmental Glomerulosclerosis (FSGS) (2023)

Journal of the American Society of Nephrology 2 citations DOI OpenAlex
Nrf2 Activation in the Glomeruli and Podocytes: Deciphering the Renal Mechanisms of Nrf2 (2023)

Kidney360 4 citations DOI OpenAlex
SOD1 is a novel prognostic biomarker of acute kidney injury following cardiothoracic surgery (2023)

BMC Nephrology 4 citations DOI OpenAlex
High-Cutoff Hemodialysis Therapy for Patients with Light Chain Cast Nephropathy and AKI Requiring Dialysis: CON (2023)

Kidney360 DOI OpenAlex